Zobrazeno 1 - 10
of 302
pro vyhledávání: '"Transthyretin amyloid cardiomyopathy"'
Autor:
Takuya Iino, Manabu Nagao, Hidekazu Tanaka, Sachiko Yoshikawa, Junko Asakura, Makoto Nishimori, Masakazu Shinohara, Amane Harada, Shunsuke Watanabe, Tatsuro Ishida, Ken-ichi Hirata, Ryuji Toh
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract The pathophysiology of variant transthyretin (TTR) amyloidosis (ATTRv) is associated with destabilizing mutations in the TTR tetramer. However, why TTR with a wild-type genetic sequence misfolds and aggregates in wild-type transthyretin amyl
Externí odkaz:
https://doaj.org/article/0649b95f344746439c3c1bbcebaf3940
Autor:
Eman S. AL_Akhali, Sultan A. Alshoabi, Abdullgabbar M. Hamid, Kamal D. Alsultan, Awatif M. Omer, Mohammed A. Alhammadi
Publikováno v:
Radiology Case Reports, Vol 19, Iss 11, Pp 4730-4735 (2024)
Cardiac amyloidosis is indeed a condition characterized by the deposition of amyloid proteins in the myocardium, leading to thickening and stiffening of the heart muscle. These abnormal protein deposits can interfere with the heart's normal functioni
Externí odkaz:
https://doaj.org/article/0b11ea2ef16f455b84483496952c5e3c
Autor:
Eirik Aaseth, Jon R. Christiansen
Publikováno v:
ESC Heart Failure, Vol 11, Iss 2, Pp 871-876 (2024)
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is characterized by increased wall thickness, diastolic dysfunction and progressive heart failure symptoms. The disease may infiltrate the conduction system leading to conduction disturba
Externí odkaz:
https://doaj.org/article/37417323d98d4caaba590ef01bf41b47
Autor:
Qiuyan Sha, Yanli Zhang, Mengdie Wang, Jialu Sun, Yunlong Zhang, Xinxin Zhang, Ning Wang, Yu Liu, Ying Liu
Publikováno v:
ESC Heart Failure, Vol 11, Iss 1, Pp 112-125 (2024)
Abstract Aims We conducted a presentation on an 84‐year‐old male patient who has been diagnosed with TTRA81V (p. TTRA101V) hereditary transthyretin cardiac amyloidosis (hATTR‐CM). In order to establish its pathogenicity, we extensively investig
Externí odkaz:
https://doaj.org/article/e6ed4631d952469c8912ad10713aba82
Autor:
Maximilian Leo Müller, Ekaterina Latinova, Anna Brand, Isabel Mattig, Sebastian Spethmann, Daniel Messroghli, Katrin Hahn, Ulf Landmesser, Bettina Heidecker
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 14 (2024)
Background Results from ATTR‐ACT (Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy) indicate that tafamidis prolongs survival and reduces cardiovascular hospitalizations in cardiac transthyretin amyloidosis (ATTR‐CA)
Externí odkaz:
https://doaj.org/article/d5882afb77134ed4b953157ff190df27
Autor:
Bertil Ladefoged, Anders Dahl Pedersen, Jacob Seefeldt, Bent Roni Ranghøj Nielsen, Hans Eiskjær, Emil Lichscheidt, Tor Clemmensen, Julian David Gillmore, Steen Hvitfeldt Poulsen
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 13 (2024)
Background Wild‐type transthyretin amyloid (ATTRwt) cardiomyopathy is increasingly recognized in the development of heart failure. The link between cardiac performance, hemodynamics, and mitochondrial function in disease stages of ATTRwt has not pr
Externí odkaz:
https://doaj.org/article/36e4897fdd884b93ac55e5daa71d5e5b
Autor:
Giacomo Urbinati, Ilaria Cani, Marco Currò Dossi, Simone Longhi, Samuela Carigi, Christian Gagliardi, Elena Biagini, Nazzareno Galiè, Pietro Cortelli, Pietro Guaraldi
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
ObjectivesEvidence on the activity of patisiran therapy in specific subgroups of patients with hereditary transthyretin amyloidosis variant (ATTRv) is still scarce. This prospective real-world study was designed to provide the first in-depth clinical
Externí odkaz:
https://doaj.org/article/6d48eaa8280b4f93b36312858de5a918
Autor:
Naoto Kuyama, Seiji Takashio, Tetsuya Oguni, Masahiro Yamamoto, Kyoko Hirakawa, Masanobu Ishii, Shinsuke Hanatani, Seitaro Oda, Yasushi Matsuzawa, Hiroki Usuku, Eiichiro Yamamoto, Toshinori Hirai, Mitsuharu Ueda, Kenichi Tsujita
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 10 (2024)
Background Although tafamidis treatment improves prognosis in patients with wild‐type transthyretin amyloid cardiomyopathy, an optimal surrogate marker monitoring its therapeutic effect remains unclear. This study investigated the association betwe
Externí odkaz:
https://doaj.org/article/93a70a17e0074eafbf76289150ed1dc2
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
Hereditary transthyretin amyloid (ATTRv) cardiomyopathy (CM) is caused by mutations in the TTR gene. TTR mutations contribute to TTR tetramer destabilization and dissociation, leading to excessive deposition of insoluble amyloid fibrils in the myocar
Externí odkaz:
https://doaj.org/article/cbf760c9dadc4dd7ae7279bc0c7eb0eb
Autor:
Ana Moya, Clara L. Oeste, Monika Beles, Sofie Verstreken, Riet Dierckx, Ward Heggermont, Jozef Bartunek, Eline Bogaerts, Imke Masuy, Dries Hens, Dario Bertolone, Marc Vanderheyden
Publikováno v:
ESC Heart Failure, Vol 10, Iss 6, Pp 3483-3492 (2023)
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM), a progressive and fatal cardiomyopathy, is frequently misdiagnosed or entails diagnostic delays, hindering patients from timely treatment. This study aimed to generate a systematic frame
Externí odkaz:
https://doaj.org/article/c6ce75b94ab64243a968f0a0fd0a2328